<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95144">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866254</url>
  </required_header>
  <id_info>
    <org_study_id>13527</org_study_id>
    <nct_id>NCT01866254</nct_id>
  </id_info>
  <brief_title>Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries</brief_title>
  <official_title>Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grace Shih, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Masimo Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if intrathecal hydromorphone will relieve pain as
      well as intrathecal morphine after cesarean delivery, with fewer side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intrathecal morphine has long been the standard pain medication used in cesarean sections.
      Since some patients cannot tolerate morphine, hydromorphone may be an acceptable
      alternative. Intrathecal Intrathecal hydromorphone has been shown to be effective at
      treating post cesarean section pain and possibly with less side effects than morphine.

      One side effect of morphine is respiratory depression occurring hours after the start of
      morphine use. Respiratory depression occurs when air being taken into the lungs is less than
      normal, leading to a lower amount of oxygen and carbon dioxide being exchanged in the blood
      stream. Because hydromorphone dosages are lower and it has a quicker onset of action than
      morphine, it is believed that the use of hydromorphone should decrease the possibility of
      delayed respiratory depression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Scores</measure>
    <time_frame>from Baseline to 24 Hours</time_frame>
    <description>Pain scores to be measured using the verbal response scale (VRS). The VRS pain score is measured on a scale of 0-10 with 0 representing absolutely no pain and 10 representing worst pain imaginable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>up to 24 Hours</time_frame>
    <description>Patients will be monitored hourly for first 12 hours followed by every 2 hours for the next 12 hours. Masimo acoustic monitor will monitor respirations.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Hydromorphone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg, intrathecal administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg, intrathecal administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>Injection of 100 mcg hydromorphone into the intrathecal space</description>
    <arm_group_label>Hydromorphone</arm_group_label>
    <other_name>DILAUDIDÂ® INJECTION</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Injection of 200 mcg of intrathecal morphine</description>
    <arm_group_label>Morphine</arm_group_label>
    <other_name>Duramorph</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for elective Cesarean sections under spinal anesthesia or combined spinal
             anesthesia

          -  ASA status of I-III

          -  BMI &lt; 40

          -  Able to understand and sign informed consent

        Exclusion Criteria:

          -  Severe pre-eclampsia

          -  Conversion to general anesthetic

          -  History of chronic opioid use

          -  Allergy to morphine, or hydromorphone

          -  Hyperemesis gravidarum

          -  Emergency case

          -  Patients who have an infection at the intended site of spinal insertion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace Shih, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angie Ballew</last_name>
    <phone>913-945-7420</phone>
    <email>aballew@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katherine Stiles, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin DeRuyter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Thomas-Dodson, RN, BSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 2, 2017</lastchanged_date>
  <firstreceived_date>May 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Grace Shih, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hydromorphone</keyword>
  <keyword>Morphine</keyword>
  <keyword>cesarean delivery</keyword>
  <keyword>pain management</keyword>
  <keyword>respiratory depression</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
